JeremiahBrownJr.MDM.S.

Ophthalmology • Schertz, TX

Retinal Disease, Uveitis

Brown Retina Institute

Join to view full profile

Dr. Brown is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brown's full profile

Already have an account?

Office
17319 Interstate 35 N
Ste 303
Schertz, TX 78154
Phone+1 210-693-1063

Fax+1 830-214-2718

Education & Training

U Iowa Hosps and Clinics1998
University of Iowa Hospitals and ClinicsResidency, Ophthalmology, 1996
Hartford Hospital1991 - 1992
University of California San Francisco School of MedicineClass of 1991
Univ of California, BerkeleyM.S., Health Policy, 1986 - 1989
Harvard CollegeB.A., Biology, 1981 - 1985

Certifications & Licensure

IA State Medical License 1992 - 2025
TX State Medical License 2000 - 2025
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow ASRS American society of Retina Specialists, 2020
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
TERMINATED
PHASE3
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) Start of enrollment: 2018 Sep 25
Terminated
Phase 3
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD Start of enrollment: 2021 Mar 04
ACTIVE_NOT_RECRUITING
PHASE3
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Start of enrollment: 2018 Aug 31
Completed
Phase 3
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) Start of enrollment: 2018 Oct 01
COMPLETED
PHASE3
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders Start of enrollment: 2020 Oct 01
COMPLETED
PHASE3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Start of enrollment: 2021 Dec 28
RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

9 citations
The efficacy of multifaceted versus single anesthesia work area infection control measures and the importance of surgical site infection follow-up duration.
Franklin Dexter, Jeremiah R Brown, Russell T Wall, Randy W Loftus
Journal of Clinical Anesthesia. 2023-05-01
7 citations
Galectin-3 as a Predictor of Long-term Survival After Isolated Coronary Artery Bypass Grafting Surgery.
Devin M. Parker, Sherry L. Owens, Niveditta Ramkumar, Donald S. Likosky, Anthony W. DiScipio
The Annals of Thoracic Surgery. 2020-01-01
6 citations
Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery.
Niveditta Ramkumar, Jeffrey P. Jacobs, Richard B. Berman, Devin M. Parker, Todd A. MacKenzie
The Annals of Thoracic Surgery. 2019-12-01

Press Mentions

AMD, DME Therapies Aimed at Reducing Treatment Burden Shine at AAO 2024November 1st, 2024
Diabetic Eye Disease Worst in Hispanic and Latino Patients, but Treatment Response More RobustOctober 22nd, 2024
Genentech’s Vabysmo Improved Vision in Underrepresented Populations with Diabetic Macular Edema (DME) in a First-of-Its-Kind StudyOctober 18th, 2024
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow

Other Languages

Spanish

External Links

Brown Retina Institutehttp://www.jeremiahbrownmd.com